Attached files
| file | filename |
|---|---|
| EX-31.2 - VIVOS INC | ex31-2.htm |
| EX-31.1 - VIVOS INC | ex31-1.htm |
| EX-10.6 - VIVOS INC | ex10-6.htm |
| EX-10.5 - VIVOS INC | ex10-5.htm |
| EX-10.4 - VIVOS INC | ex10-4.htm |
| EX-10.3 - VIVOS INC | ex10-3.htm |
| EX-10.2 - VIVOS INC | ex10-2.htm |
| EX-10.1 - VIVOS INC | ex10-1.htm |
| 10-Q - VIVOS INC | form10-q.htm |
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying quarterly report of Advanced Medical Isotope Corporation (the “Company”) on Form 10-Q for the quarter ended June 30, 2017 (the “Report”), the undersigned, Michael Korenko, Chief Executive Officer of the Company, and L. Bruce Jolliff, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: August 11, 2017 | ||
| By: | /s/ Michael K. Korenko | |
| Name: | Michael K. Korenko | |
| Title: | Chief Executive Officer |
| By: | /s/ L. Bruce Jolliff | |
| Name: | L. Bruce Jolliff | |
| Title: | Chief Financial Officer |